Related Experiment Video
Updated: May 31, 2026

In Vivo Imaging Systems (IVIS) Detection of a Neuro-Invasive Encephalitic Virus
Published on: December 2, 2012
JC virus-induced Progressive Multifocal Leukoencephalopathy
A Sami Saribas1, Ahmet Ozdemir, Cathy Lam
1Department of Neuroscience and Center for Neurovirology, Temple University School of Medicine, Education & Research Building (MERB-757), 3500 North Broad Street-7th floor, Philadelphia, PA 19140-5104.
Abstract:
Progressive multifocal encephalopathy (PML) is a fatal demyelinating disease of the central nervous system (CNS), caused by the lytic infection of oligodendrocytes by a human polyomavirus, JC virus (JCV). PML is rare disease but mostly develops in patients with underlying immunosuppressive conditions, including Hodgkin's lymphoma, lymphoproliferative diseases, in those undergoing antineoplastic therapy and AIDS. However, consistent with the occurrence of PML under immunocompromised conditions, this disease seems to be also steadily increasing among autoimmune disease patients (multiple sclerosis and Crohn's disease), who are treated with antibody-based regimens (natalizumab, efalizumab and rituximab). This unexpected occurrence of the disease among such a patient population reconfirms the existence of a strong link between the underlying immunosuppressive conditions and development of PML. These recent observations have generated a new interest among investigators to further examine the unique biology of JCV.
Insights
Progressive multifocal encephalopathy (PML), a fatal CNS disease caused by JC virus (JCV), is increasing in autoimmune patients on antibody therapies. This highlights the link between immunosuppression and PML development, prompting further JCV research.
Area of Science:
- Neuroscience
- Virology
- Immunology
Background:
- Progressive multifocal encephalopathy (PML) is a fatal demyelinating central nervous system (CNS) disease.
- PML results from JC virus (JCV) infection of oligodendrocytes.
- It typically affects immunocompromised individuals, including those with cancers, undergoing chemotherapy, or with AIDS.
Purpose of the Study:
- To examine the increasing incidence of PML in patients with autoimmune diseases.
- To investigate the role of antibody-based therapies in PML development.
- To re-evaluate the link between immunosuppressive conditions and JCV pathogenesis.
Main Methods:
- Review of recent epidemiological data on PML incidence.
- Analysis of patient populations undergoing specific immunosuppressive treatments.
- Correlation of PML occurrence with underlying autoimmune conditions and therapeutic regimens.
Main Results:
- PML incidence is rising in patients with multiple sclerosis and Crohn's disease.
- These patients are often treated with antibody-based therapies like natalizumab, efalizumab, and rituximab.
- The data reinforce the association between immunosuppression and PML development.
Conclusions:
- The increasing occurrence of PML in autoimmune patients treated with antibody therapies underscores the critical role of immunosuppression.
- These findings necessitate further investigation into the unique biology of JCV and its interaction with the immune system.
- Understanding these mechanisms is crucial for managing PML risk in vulnerable patient populations.
Related Concept Videos
Encephalitis ll: Pathophysiology
Arboviral Encephalitis
Cytomegalovirus Disease
Encephalitis l: Introduction
Cryptococcal Meningitis
Viral Meningitis

